Xeris Biopharma Holdings, Inc. cash flow to debt ratio of 75.80% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Xeris Biopharma Holdings, Inc.'s free cash flow has increased -173.79% from $-37.85M last year to $27.93M, signaling increasing performance

Xeris Biopharma Holdings, Inc.'s debt to equity ratio is 2.87, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Xeris Biopharma Holdings, Inc.'s debt has increased relative to shareholder equity from -9.17 last year to 2.87 today, signaling weakened financials

Xeris Biopharma Holdings, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Xeris Biopharma Holdings, Inc.'s interest coverage ratio is 1.25, which means that the company struggles to meet interest obligations, signaling financial risk.

Xeris Biopharma Holdings, Inc.'s profit margin has increased (-114.12%) in the last year from -27.00% to 3.81%, signaling increasing performance

Xeris Biopharma Holdings, Inc.'s short-term assets of $240.31M exceed its short-term liabilities of $109.57M

Xeris Biopharma Holdings, Inc.'s return on assets of 3.06% is lower than the 5.00% threshold, indicating inefficient asset utilization

Xeris Biopharma Holdings, Inc.'s return on equity of 735.00%, is higher than 15.00%, indicating good performance

Xeris Biopharma Holdings, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Xeris Biopharma Holdings, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Xeris Biopharma Holdings, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Xeris Biopharma Holdings, Inc. has a free cash flow yield of 1.95%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Xeris Biopharma Holdings, Inc.'s yearly earnings has increased -101.01% since last year from $-54.84M to $554.00K, signaling increasing performance

Xeris Biopharma Holdings, Inc.'s yearly revenue has increased 43.72% since last year from $203.07M to $291.85M, signaling increasing performance

ROIC 12.84% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Xeris Biopharma Holdings, Inc.'s 3-year revenue CAGR of 38.33% is positive, indicating growing revenue over the past 3 years

Xeris Biopharma Holdings, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Xeris Biopharma Holdings, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Xeris Biopharma Holdings, Inc. has insufficient data to evaluate this check.

Xeris Biopharma Holdings, Inc. has an earnings yield of 0.85%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Xeris Biopharma Holdings, Inc. is overvalued relative to its fair value price of 0.95 based on EBITDA multiple model

Xeris Biopharma Holdings, Inc. has an EV/EBITDA ratio of 106.70x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Xeris Biopharma Holdings, Inc. is overvalued relative to its fair value price of -8.78 based on Earnings Fair Value model

Xeris Biopharma Holdings, Inc. has a PEG-ratio under 1 which is considered undervalued

Xeris Biopharma Holdings, Inc. has a price-to-book ratio of 108.52x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Xeris Biopharma Holdings, Inc. has a price-to-sales ratio of 4.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue